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Abstract
Background: The molecular basis of severe acute respiratory syndrome (SARS) coronavirus
(CoV) induced pathology is still largely unclear. Many SARS patients suffer respiratory distress
brought on by interstitial infiltration and frequently show peripheral blood lymphopenia and
occasional leucopenia. One possible cause of this could be interstitial inflammation, following a
localized host response. In this study, we therefore examine the immune response of SARS-CoV
in human peripheral blood mononuclear cells (PBMCs) over the first 24 hours.
Methods: PBMCs from normal healthy donors were inoculated in vitro with SARS-CoV and the
viral replication kinetics was studied by real-time quantitative assays. SARS-CoV specific gene
expression changes were examined by high-density oligonucleotide array analysis.
Results: We observed that SARS-CoV was capable of infecting and replicating in PBMCs and the
kinetics of viral replication was variable among the donors. SARS-CoV antibody binding assays
indicated that SARS specific antibodies inhibited SARS-CoV viral replication. Array data showed
monocyte-macrophage cell activation, coagulation pathway upregulation and cytokine production
together with lung trafficking chemokines such as IL8 and IL17, possibly activated through the TLR9
signaling pathway; that mimicked clinical features of the disease.
Conclusions: The identification of human blood mononuclear cells as a direct target of SARS-CoV
in the model system described here provides a new insight into disease pathology and a tool for
investigating the host response and mechanisms of pathogenesis.
Background
The causative agent for SARS has been identified as a
novel coronavirus [1-3] with genome sequence revealing
no strong homology to existing known coronaviruses [4-
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viruses called Coronaviridae, and have the largest known
single-stranded viral RNA genomes (27 to 32 kb). Coro-
naviruses, have both "early" and "late" phases of gene
expression. Regulatory proteins are synthesized as "early"
non-structural proteins, while the structural proteins are
synthesized as "late" proteins. "Late" structural proteins
are usually required in greater amounts thus, there is a
necessity to regulate the expression of the viral genes
quantitatively. After the viral entry via endocytosis or
through specific receptors, the 5'-end of the viral genome
is translated directly giving rise to twenty-three viral pro-
teins, including the RNA dependent RNA polymerase
(RdRp), and other functional products involved in tran-
scription, replication, viral assembly and cell death. Coro-
naviruses can be classified into species and three major
antigenic groups based on, serology, natural hosts, mono-
clonal antibody recognition and nucleotide sequencing
[7]. Most coronaviruses have restricted host ranges as they
infect only one host species or, at most, a few related spe-
cies, they are an important group of animal pathogens.
Group one (I) includes human coronavirus 229E (HCoV),
porcine transmissible gastro-enteritis virus (TGEV) and
feline enteric coronavirus (FECoV). Group two (II)
includes bovine coronavirus (BCoV), murine hepatitis
virus (MHV), and HCoV-OC43; and Group three (III)
includes avian infectious bronchitis virus (IBV) [7]. Some
coronaviruses like HCoV have restricted tissue tropism,
including macrophages [8], although most strains that
infect humans cause only mild respiratory infections.
However, SARS has rapidly caused a world-wide problem.
The earliest known cases of SARS was reported in Guan-
dong Province, China in November 2002, becoming
more widespread by March 2003, when it was introduced
to Canada, Singapore, Taiwan and Vietnam via Hong
Kong. The largest number of infected patients has been in
China with a worldwide incidence totalling more than
8,400 by July 2003. Infection by the virus induces high
morbidity and mortality, the latter being estimated at
15% by the World Health Organisation. SARS is character-
ized by high fever, non-productive cough or dyspnea and
in many cases may progress to generalized, interstitial
infiltrates in the lung, thus needing intubation and
mechanical ventilation [2]. The characteristic compres-
sion of alveolar sacs seen in atypical pneumonia is largely
due to fluid build up outside the alveoli. One possible
cause of this could be interstitial inflammation, following
a localised host response. To date, the details of the host
response to SARS-CoV infection is still largely unknown
and consequently the most appropriate treatment regime
remains to be established. Typically a pro-inflammatory
cytokine profile (up regulated TNFα, Il1, IL6 and IFNs) is
seen in viral infections such as influenza [9], together with
perhaps limited amounts of IL8 and other chemokines
[10] that may depend on which cell type is infected [11].
In experimental systems the immediate innate immune
response has been shown to be directed by the monocyte-
macrophage-dendritic lineage to a range of different
organisms [12,13] and consists of a core set of pathways
common to all, together with pathogen specific pathways.
This data points to critical time points in the response,
with the first 12 hours representing primary events while
longer periods the consequence of this activity and a sec-
ondary (perhaps larger) cascade of responses.
We postulated that the pulmonary damage in SARS may
not be a direct effect of the virus on the alveoli, but repre-
sents a secondary effect of cytokines or other factors prox-
imal to but not from the lung tissue mediated by the host
either as the primary or secondary response [2,14]. In this
study, we have addressed this question by developing a
human in vitro model system that will in the future allow
detailed investigations of the host response to be made.
Methods
Cell culture and virus infection
PBMCs were obtained by Ficoll-Hypaque separation of
whole blood. 2 × 105 PBMCs were seeded into each well
of a 24-well culture plate, 0.5 ml of complete RPMI-1640
(Life Technologies-Invitrogen, USA) added to each and
cultured overnight at 37°C (5% CO2). A seed stock of
SARS-CoV (strain SIN 2774) passaged in Vero E6 cells was
used for infection. Vero E6 culture supernatants were
added to each well in 50 µl volume at a concentration of
0.1 or 0.01 MOI (based on plaque forming units) and a
control plate (media only). Each culture was set up in
duplicate. After 4 hours of incubation, one set of the
duplicate wells of the control plate and a 4 hours incuba-
tion plate were harvested while the rest received 0.5 ml
media top-up and incubated for a further 2, 4, 6 and 8
days.
Cell harvest and RNA isolation
Harvesting was performed by gently flushing the wells
with a Pasteur pipette to removed non-adherent cells, fol-
lowed by a rinse of 1 ml RPMI. The rinsed fraction was
pooled with the first harvest aliquot and spun at 1500
rpm. The cell pellet was washed twice with 2 ml RPMI to
remove virus in the supernatant. 1.5 ml Trizol (Invitrogen,
USA) was then added to the adherent cell fraction as well
as the non-adherent cell fraction to lyse cells and stabilize
the RNA. Extraction of total RNA was then performed fol-
lowing manufacturer's protocol and the resultant RNA
dissolved in 40 µl water.
Real-time quantitative polymerase chain reaction (PCR)
The amount of SARS-CoV in each cell fraction was meas-
ured by real-time quantitative PCR assay. 2 µl of RNA was
reverse transcribed and amplified in 20 µl using 0.9 µMPage 2 of 11
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and reverse (5'-AGAACAAGAGAGGCCATTATCCTAAG-
3') primers, and 0.25 µM of TaqMan® MGB probe: 5'-(6-
FAM)AGAGCCATGCCTAACAT(NFQ)-3') in a one step
PCR using master mix from Applied Biosystems (USA)
according to manufacturers' recommendations. Reactions
were performed using an ABI PRISM 7900 sequence detec-
tion system (48°C for 30 min, followed by 95°C for 10
min and 40 cycles of 95°C for 15 sec and 60°C for 1 min)
and quantitation achieved using standard curves gener-
ated from in vitro transcribed RNA.
High density oligonucleotide array hybridization
At each time point (4 hours, 8 hours, 12 hours, 24 hours),
5 × 107 cells of mock-infected and infected cells were har-
vested and lysed using Trizol (Invitrogen, USA). Total
RNA was isolated according to the manufacturer's recom-
mendation. Quality of the total RNA was judged from the
ratio between 28S and 18S RNA after agarose gel electro-
phoresis. 20 µg of total RNA was labeled with Cy-3 or Cy-
5 using the Superscript II reverse-transcription kit (Invitro-
gen, USA) and hybridization was carried out overnight
(16 hours) at 42°C on high-density oligonucleotide
arrays (~19,200 gene features, Compugen) using univer-
sal human reference (Stratagene, USA) as a reference.
Hybridized arrays were scanned at 5 µm resolution on a
GenePix 4000A scanner (Axon Instruments) with variable
photo-multiplier tube voltage to obtain maximal signal
intensities, and the resulting images were analyzed via
GenePix Pro v4.0 (Axon Instruments) as described in the
manual.
Microarray data analysis
Raw data were analyzed on GenePix analysis software ver-
sion 4.0 (Axon Instruments) and uploaded to a relational
database. The logarithmic expression ratio for a spot on
each array was normalized by subtracting the median log-
arithmic ratio for the same array. Data were filtered to
exclude spots with a size of less than 25 µm and any poor
quality or missing spots. Since the correlation of the over-
all data from reciprocal labeling was good, values
obtained from reciprocal labeling experiments were aver-
aged. In addition, the data were distilled to the set of gene
features that were present at all 4 time points in both the
viral infected samples and the negative controls. The
results were represented as the logarithmic ratio of gene
expression between the viral infected samples and their
corresponding negative controls at the various time
points. Application of these filters resulted in the inclu-
sion of ~12,900 of the total ~19,200 gene features in sub-
sequent analyses.
To discover patterns of gene expression, the values associ-
ated with each gene feature f were translated so that their
means were zero. Similar genes, whose translated gene-
features exhibited same induction-repression pattern,
were grouped together. Genes gi, gj were said to be similar
if they satisfied the following condition:
, where U(x) = 1 if x > 0, U (x) = 0
otherwise,
where git and gjt denote the translated values of gene fea-
tures gi, gj at time t respectively; and N is the number of
time points for which the expression of a gene was
observed. Similar genes, based on the above criteria, are
grouped together. Within each group, the genes were
ordered in the descending order of their expression range
(defined as the difference between the maximum and
minimum ratios of gene expression). This algorithm is a
special case of the Friendly Neighbor algorithm currently
under development. The final plots were generated using
the original expression ratios while preserving the cluster-
ing and ordering discovered by the above algorithm. To
determine whether a gene observed to be responsive
could appear merely by chance, 100,000 expression pro-
files were generated by randomly sampling the expression
ratios from the entire dataset with replacement. The P
value of a gene is the fraction of the random profiles
whose logarithmic expression range is as good as, or better
than that of the selected gene.
Results and Discussion
Kinetics of SARS-CoV replication
We obtained PBMCs from 6 healthy volunteers by Ficoll-
Hypaque separation of whole blood. Of the 6 donor
PBMCs tested, all were able to support SARS-CoV replica-
tion when infected with multiplicity of infection (MOI) of
0.1. The first sampling, taken from cells infected for 4
hours, showed an average copy number of 32 × 103 (Fig.
1A) and represents the initial inoculum level. Over the
course of the next 8 days, there was a steady rise in viral
load, reaching as high as 480 × 103 copies per well in one
donor, which could only be explained by active replica-
tion of the SARS-CoV intracellularly. This work is sup-
ported by recent in vivo evidence suggesting that SARS-
CoV may have infected and replicated within PBMCs of
SARS patients [15] and cells from humans and animals
[16]. An indication of the PBMCs lineage involvement
was provided by repeating the experiment using the
monocyte-macrophage cell line THP-1 [17], in which viral
replication was similar to the primary cell culture over the
first 4 days (Fig. 1B). In the primary cultures, the non-
adherent cell fraction which comprises mainly lym-
phocytes and granulocytes showed dramatically less viral
replication in our assay as did all cells infected at MOI of
0.01 (Fig. 1A).
The kinetics of viral replication was variable among the 6
donors (Fig. 1C). There was a lag phase of 2 days in the
U g g Nit jtt ( * ) =∑Page 3 of 11
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Kinetics of SARS-CoV replication. A. Viral copy number per well during culture. Two MOI infecting doses were used, 0.1 
(▲,■) and 0.01 (,) with 2 × 105 PBMCs/well. Harvested PBMCs were separated into two fractions, adherent cells (mostly 
macrophages), (■,) and suspended cells (mostly lymphocytes), (▲,). Points represent the mean of six subjects, each done 
in duplicate. Increasing viral copy number is clearly seen in adherent cells using an MOI of 0.1. There was little increase in viral 
load in non-adherent cells infected with SARS- CoV. B. Replication of SARS-CoV in the THP-1 cell line. Using an MOI of 0.1, 
fold increase from day 0 in SARS-CoV infected THP-1 cells (◆) was similar to the PBMCs adherent fraction (▲). Infections 
were done in duplicate and assayed in duplicate. Error bars represent SEM. C. Variation in the PBMC response to SARS-CoV 
infection. Using an MOI of 0.1 adherent cells (■) but not suspended cells (▲) showed differing lag phase length and viral repli-
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before any significant increase could be detected. The viral
replication generally peaked at either day 4 or day 6. The
exception was donor b, in which the virus seemed to rep-
licate at a much slower pace compared to the other 5
donor samples. Equally interesting was the different levels
of virus attained. Donor d seems to stand out from the
rest, reaching a peak of 480 × 103 copies per well which is
4 times more than that attained by donor e, with 120 ×
103 copies per well. Such variation strongly suggests that
there is an underlying host-pathogen interaction influenc-
ing the kinetics of SARS-CoV replication efficiency. These
in vitro observations may reflect the wide range of patient
outcomes after SARS-CoV infection [18].
Antibody blocking experiments were also performed in
which SARS-CoV was pre-incubated with convalescent
patient sera for 30 minutes before introduction to the
PBMCs and after a 4 day incubation period, the adherent
cell fraction was harvested and assayed for SARS-CoV viral
titer. Results clearly showed that even at high dilution,
convalescent sera inhibited SARS viral replication (data
not shown), presumably by blocking viral entry. This sup-
ports other reports indicating that SARS-CoV is not endo-
cytosed through antibody mediated mechanisms and
confirms a protective role for antibodies elicited either by
the infection or through immunization [19,20].
SARS-CoV specific gene expression changes
To further elucidate the molecular processes of SARS-CoV
infection, PBMCs from 3 healthy individuals were
infected separately in vitro with SARS-CoV (0.1 MOI) and
harvested at 4 hours, 8 hours, 12 hours and 24 hours time
intervals post-infection. As controls, uninfected aliquots
of the same PBMCs were also harvested at the correspond-
ing time points. Total RNA extracted from the PBMCs of
the 3 individuals were pooled, labeled and hybridized to
human oligonucleotide arrays consisting of ~19,200 gene
features. Reciprocal dye swap replicate hybridizations
were performed to minimize technical noise. Analysis of
variance in expression levels for each gene across all the
time points indicated the ~1200 genes which showed the
largest variability (Fig. 2A and 2B).
In order to focus the analysis, we queried the entire data
set for genes related to the immune response by keyword
searches on their gene ontology descriptions with the aim
of describing the specific host-pathogen interaction. In
common with other studies of respiratory pathogens [9-
13], our data points towards two critical time points in the
response, with the first 12 hours representing a primary
pro-inflammatory cytokine profile while longer periods
represent the consequence of this activity and a secondary
cascade of responses [9-13]. We observed that within the
first 12 hours of SARS-CoV infection, evidence of this
monocyte-macrophage activation was seen, indicated by
enhanced expression of CD14, TLR9 plus NFKβ1 and
GATA signaling (Fig. 2C and Table 1). In addition, the
MRC2 endocytotic receptor was upregulated as was the
complement pathway (C1q, C6). Taken together, these
data suggest an early activation of the innate immunity
pathway. This activation was accompanied by an unusual
cytokine transcriptional profile (Fig. 2C and Table 1).
While IL1β (up regulated for the first 12 hours) would be
expected following macrophage activation [21], TNFα,
IFNγ and IL6 were noted by their surprisingly low level of
expression. This is in spite of the presence of elevated IL19
which is thought to enhance their up regulation [22]. In
some clinical investigation, concentrations of TNF and IL
6 measured during active disease were found to be rela-
tively low [23,24], reflecting our findings. This paper did
not report on IFN levels, however, we found them to be
low (Supplementary figure [see Additional file 1]). This is
of particular interest as IFNs have been shown to have sig-
nificant anti-SARS-CoV effects [25]. Such effects suggest
that alteration of the IFN response and perhaps other
immune modulators might provide opportunity for novel
treatment and management regimes for SARS patients to
be developed.
A number of CC chemokines (CCL4, CCL20, CCL22,
CCL25, CCL27) and their receptors (CCR4 and CCR7)
were highly expressed in response to the infection (Fig. 2C
and Table 1), indicating a rapid mobilization and
increased trafficking, in particular of the monocyte-mac-
rophage lineage very early on in the infection [26]. CXC
chemokines (CXCL9, CXCL12) were also highly expressed
suggesting significant increase in neutrophil homing as
well. These are likely to be lung directed as IL8 and IL17
were also highly expressed [27-32]. Specific trafficking of
these cells to the lung may account for the localized nature
of the response [33].
Surprisingly, a number of blood coagulation genes were
highly expressed early during our in vitro infection (Fig.
2C and Table 1), in particular TBXAS, which has been
implicated in vasoconstriction, platelet aggregation,
membrane lysis and increased permeability [34,35];
fibrin (FGB and FGG) and the coagulation pathway
directly (SERPINs D1 and A3 together with Factors 10, 3
and 2). This gives a pro-coagulation profile, which mimics
the clinical-pathological observations: at autopsy, many
SARS patients have unusually disseminated small vessel
thromboses in the lungs without evidence of dissemi-
nated intravascular coagulation [1,36]. Again, these
expression profiles provide an experimental framework to
explore an important aspect of SARS pathobiology and
treatment.Page 5 of 11
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BMC Infectious Diseases 2004, 4:34 http://www.biomedcentral.com/1471-2334/4/34SARS specific gene expression changesFigure 2
SARS specific gene expression changes. A. Plot showing the variance of expression ratio for each of the gene features across all 
the time points. Dotted line indicates the ~1200 most variable gene features. B. Expression ratios of ~1200 gene features as 
grouped by the algorithm as discussed in Methods. Rows represent individual genes, columns represent individual time points. 
Each cell in the matrix represents the mean expression level from 3 subjects for a gene feature at a particular time point (non-
infected PBMCs responses have been subtracted from infected responses). The red and green color bars reflect high and low 
expression levels respectively, while black indicates equivalent expression level. The magnitude of the log-transformed ratio is 
reflected by the degree of color saturation. C. Levels of PBMCs mRNA expression of 1087 immune-related genes at 4 hours, 8 
hours, 12 hours, and 24 hours in response to SARS-CoV infection were grouped and ordered using the algorithm described in 
Methods. Rows represent individual genes, columns represent individual time points. Each cell in the matrix represents the 
mean expression level from 3 subjects for a gene feature at a particular time point (non-infected PBMCs responses have been 
subtracted from infected responses). The red and green color bars reflect high and low expression levels respectively, while 
black indicates equivalent expression level. The magnitude of the log-transformed ratio is reflected by the degree of color sat-
uration. The line graph indicates the average expression ratios for each group. The area above the axis indicates upregulation, 
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1083997 NEK1; 1083997; Hs.48332
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1085005 JMJ; 1085005; Hs.40154
1078796 CARM1; 1078796; Hs.143696
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1083559 MATR3; 1083559;
1083183 FLJ12960; 1083183; Hs.45005
1077381 SS18L1; 1077381; Hs.154429
1084120 BPAG1; 1084120;
1076449 SCAM-1; 1076449; Hs.33787
1091506 CHORDC1; 1091506; Hs.22857
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1085998 EPB41L4B; 1085998; Hs.267997
1094254 KIAA1340; 1094254; Hs.51743
1078951 PDZ-GEF1; 1078951; Hs.154545
1085256 ; 1085256; Hs.350106
1089822 ; 1089822;
1086102 TNFRSF13B; 1086102; Hs.158341
1076404 CXorf2; 1076404; Hs.115365
1083796 MLL; 1083796;
1083494 MGC27165; 1083494;
1093851 ZFYVE1; 1093851; Hs.20047
1077586 MMP2; 1077586; Hs.111301
1094043 DRP2; 1094043; Hs.159291
1086149 NCAM2; 1086149; Hs.177691
1092958 ; 1092958;
1086147 GEMIN5; 1086147; Hs.25882
1084348 DIS3; 1084348; Hs.323346
1080486 PRO2435; 1080486; Hs.209887
1076377 FLJ10979; 1076377; Hs.149797
1077347 FLJ11171; 1077347; Hs.72782
1077941 GIF; 1077941; Hs.110014
1092416 ; 1092416; Hs.149770
1083925 TCIRG1; 1083925; Hs.46465
1092391 SLC7A1; 1092391; Hs.2928
1087861 KIAA0974; 1087861; Hs.44131
1089749 ; 1089749;
1079051 DOK4; 1079051; Hs.279832
1078607 ; 1078607;
1085203 MAP4K3; 1085203; Hs.227400
1090279 PLAC8; 1090279; Hs.107139
1094058 ; 1094058; Hs.58220
1076255 SPRY3; 1076255;
1085197 CKS2; 1085197; Hs.83758
1084096 NAB2; 1084096; Hs.159223
1086116 ; 1086116; Hs.287566
1084545 HDS; 1084545; Hs.225160
1077377 LIAS; 1077377; Hs.53531
1085869 ; 1085869; Hs.289078
1082111 ; 1082111;
1087011 PORIMIN; 1087011; Hs.172089
1092600 ADCY9; 1092600; Hs.20196
1081191 ATP7B; 1081191; Hs.84999
1079343 AIRE; 1079343; Hs.129829
1084494 PSK-1; 1084494; Hs.6314
1082011 MGC3047; 1082011; Hs.59384
1087547 FABP3; 1087547; Hs.49881
1085693 MGC27165; 1085693; Hs.146360
1077447 GSK3A; 1077447; Hs.118890
1085991 SLC12A1; 1085991; Hs.123116
1077874 ; 1077874; Hs.10268
1077643 NFIL3; 1077643; Hs.79334
1089044 CMRF35; 1089044; Hs.2605
1091694 SNN; 1091694; Hs.76691
1076605 OLFM1; 1076605; Hs.74376
1092577 KIAA1387; 1092577; Hs.301434
1088628 NME6; 1088628; Hs.343824
1082587 SRR; 1082587; Hs.27335
1089815 DKFZp434H2226; 1089815; Hs.274457
1076937 FLJ22028; 1076937; Hs.192570
1078080 KIAA1243; 1078080; Hs.151076
1077336 SAE1; 1077336; Hs.279868
1075821 ; 1075821;
1082542 FLJ20276; 1082542; Hs.270502
1076289 TM7SF2; 1076289; Hs.31130
1078023 FLJ10687; 1078023; Hs.29379
1089243 C6; 1089243; Hs.1282
1075754 DDX37; 1075754; Hs.107382
1080495 SMC5L1; 1080495; Hs.103283
1077457 ; 1077457; Hs.131887
1087742 SEC22L2; 1087742; Hs.183655
1085380 SMARCC1; 1085380; Hs.172280
1083496 NCOA3; 1083496; Hs.225977
1078253 FAP; 1078253; Hs.418
1089805 MEST; 1089805; Hs.79284
1089597 ; 1089597; Hs.82932
1080586 SMT3H2; 1080586; Hs.180139
1088194 ; 1088194;
1083138 ACACB; 1083138; Hs.183857
1093777 UGDH; 1093777; Hs.28309
1084342 KIAA0916; 1084342; Hs.151411
1082372 ; 1082372; Hs.140978
1084539 KIAA0767; 1084539; Hs.95180
1084301 TIAM1; 1084301; Hs.115176
1076490 ERAL1; 1076490; Hs.3426
1078129 ORC6L; 1078129; Hs.49760
1085236 KIAA0523; 1085236; Hs.16032
1076105 GSTM5; 1076105; Hs.75652
1083900 PACSIN1; 1083900; Hs.6462
1083459 FLJ20635; 1083459; Hs.265018
1082687 ANAPC2; 1082687; Hs.23076
1084139 FTHFD; 1084139; Hs.9520
1080693 MS4A12; 1080693; Hs.272789
1086145 FLJ20241; 1086145; Hs.181780
1093794 MFN1; 1093794; Hs.197877
1091482 WT1; 1091482; Hs.1145
1094196 PTTG2; 1094196; Hs.350966
1078043 FER1L3; 1078043; Hs.234680
1077156 LAP1B; 1077156; Hs.234265
1080011 STAT2; 1080011; Hs.72988
1090888 CA10; 1090888; Hs.283110
1087615 ; 1087615; Hs.306787
1079458 LOC284018; 1079458; Hs.90790
1090936 B3GNT3; 1090936; Hs.69009
1083854 DDX24; 1083854; Hs.155986
1089698 TNFRSF10B; 1089698; Hs.51233
1075706 ACAS2; 1075706; Hs.14779
1076451 TP53BP1; 1076451; Hs.170263
1089946 OS4; 1089946; Hs.180669
1083199 COL5A1; 1083199; Hs.146428
1085189 STS; 1085189; Hs.79876
1086450 PRKRIR; 1086450; Hs.177574
1094140 AQP7; 1094140; Hs.25475
1081929 MRPS23; 1081929; Hs.5836
1091740 SLC2A3; 1091740; Hs.7594
1077090 ASL; 1077090; Hs.61258
1079443 TMEFF1; 1079443; Hs.336224
1083785 LOX; 1083785; Hs.102267
1093300 MPP1; 1093300; Hs.1861
1085954 PAEP; 1085954; Hs.82269
1084595 TAF3; 1084595;
1085018 ; 1085018; Hs.306764
1087675 ; 1087675; Hs.118327
1076495 PLS1; 1076495; Hs.430
1082421 DKFZP434I116; 1082421; Hs.16621
1091686 SDNSF; 1091686; Hs.84775
1086554 HIRA; 1086554; Hs.172350
1079480 DNAI2; 1079480; Hs.147472
1091603 PSK; 1091603; Hs.66141
1086155 APBA1; 1086155; Hs.4880
1083643 KIAA0376; 1083643; Hs.4791
1079771 ; 1079771;
1093986 GNAZ; 1093986; Hs.92002
1076431 RORB; 1076431; Hs.198481
1085931 RARG; 1085931; Hs.1497
1086203 ARHGAP11A; 1086203; Hs.172652
1075842 CCL25; 1075842; Hs.50404
1079389 DIP2; 1079389; Hs.235160
1077901 IGFBP6; 1077901; Hs.274313
1094150 POSH; 1094150; Hs.301804
1082654 PTD004; 1082654; Hs.86347
1082043 TBC1D5; 1082043; Hs.115740
1092254 DNMT3B; 1092254; Hs.251673
1079799 TNXB; 1079799;
1092438 FLJ10846; 1092438; Hs.32271
1077181 ZNF154; 1077181; Hs.158299
1077899 COMP; 1077899; Hs.1584
1085550 CRELD1; 1085550; Hs.9383
1077138 SILV; 1077138; Hs.95972
1093946 SKP2; 1093946; Hs.23348
1077783 ZFR; 1077783; Hs.173518
1078509 ; 1078509; Hs.306888
1077087 SPUVE; 1077087; Hs.25338
1086297 BDNF; 1086297; Hs.56023
1076915 DKFZP564C196; 1076915; Hs.127384
1085336 GPLD1; 1085336; Hs.272529
1081959 ; 1081959;
1085631 PER3; 1085631; Hs.12592
1078133 PSMC5; 1078133; Hs.79387
1084250 ZFP385; 1084250; Hs.278422
1093966 ; 1093966; Hs.218008
1077814 ; 1077814;
1087947 MDS026; 1087947; Hs.85752
1085204 CETN3; 1085204; Hs.29463
1076098 MRPS22; 1076098; Hs.107127
1076391 KIAA1613; 1076391; Hs.287380
1094373 MPP5; 1094373; Hs.306219
1084530 ; 1084530; Hs.8765
1088150 P2RX7; 1088150; Hs.193470
1093725 ; 1093725;
1076394 TXN2; 1076394; Hs.211929
1085981 ; 1085981;
1087603 TAC1; 1087603; Hs.2563
1086691 SCNN1D; 1086691; Hs.112842
1088497 ; 1088497; Hs.306804
1082951 INSR; 1082951; Hs.89695
1087772 ; 1087772;
1076485 WWP1; 1076485;
1087607 TIMM8B; 1087607; Hs.279915
1077081 LOC58492; 1077081; Hs.38004
1077649 TA-LRRP; 1077649; Hs.199243
1082079 CMT2; 1082079; Hs.124
1078217 ; 1078217; Hs.306568
1077640 KIAA0176; 1077640; Hs.4935
1085596 VEGFC; 1085596; Hs.79141
1082543 CXCL12; 1082543; Hs.237356
1082292 CCRL1; 1082292; Hs.310512
1091305 PPP2R5C; 1091305; Hs.171734
1080396 PARD6A; 1080396; Hs.112933
1086130 ; 1086130; Hs.288867
1083636 PH-4; 1083636; Hs.348198
1079025 FLJ13291; 1079025; Hs.334848
1085844 RU2; 1085844; Hs.61345
1093558 NKX2-2; 1093558; Hs.159623
1083663 ; 1083663;
1087700 GPR85; 1087700; Hs.152009
1080453 NMB; 1080453; Hs.83321
1086589 DEFA4; 1086589; Hs.2582
1081996 FLJ10631; 1081996; Hs.238944
1083485 BAG5; 1083485; Hs.5443
1086352 AKAP12; 1086352; Hs.788
1087404 NASP; 1087404; Hs.243886
1093992 HOOK1; 1093992; Hs.250752
1089903 ADCY7; 1089903; Hs.172199
1093499 ITGB8; 1093499; Hs.52620
1094093 KIAA0802; 1094093; Hs.27657
1077042 SEC24C; 1077042; Hs.81964
1080411 ; 1080411;
1076590 RBP4; 1076590; Hs.76461
1084011 ANP32C; 1084011; Hs.241573
1081129 FLJ12735; 1081129; Hs.192974
1083607 FBLN2; 1083607; Hs.198862
1083481 C20orf36; 1083481; Hs.184628
1077493 MS4A5; 1077493; Hs.178066
1080443 ; 1080443; Hs.350531
1084296 LLGL2; 1084296; Hs.3123
1084246 C6.1A; 1084246; Hs.301927
1093644 NUMA1; 1093644; Hs.301512
1076448 SPTAN1; 1076448; Hs.77196
1093143 FLJ10747; 1093143; Hs.189782
1077730 THRB; 1077730; Hs.121503
1093234 ZFP36; 1093234; Hs.343586
1093193 KIAA1598; 1093193; Hs.23740
1084379 DNTT; 1084379; Hs.272537
1076251 MAP2K5; 1076251; Hs.250870
1077084 U2AF1; 1077084; Hs.59271
1076447 PFDN4; 1076447; Hs.91161
1076452 CLECSF12; 1076452; Hs.161786
1087935 PRKAG2; 1087935; Hs.259842
1090948 HGF; 1090948; Hs.809
1077279 ; 1077279;
1093205 PES1; 1093205; Hs.13501
1080536 PME-1; 1080536; Hs.63304
1094113 OMP; 1094113; Hs.248153
1092594 LIM; 1092594; Hs.154103
1081703 CACNA1A; 1081703; Hs.96253
1092357 MGC34680; 1092357;
1076349 GP1BA; 1076349; Hs.1472
1091884 EIF4G3; 1091884; Hs.25732
1093855 IMP-1; 1093855; Hs.86088
1080394 ; 1080394;
1085929 PRCP; 1085929; Hs.75693
1085194 PPP1R15A; 1085194; Hs.76556
1088930 NR2F1; 1088930; Hs.144630
1081272 FLJ39514; 1081272;
1085853 RPS6KA4; 1085853; Hs.105584
1079183 FLJ20244; 1079183; Hs.158947
1081228 HS6ST1; 1081228; Hs.6363
1078873 ; 1078873;
1082854 CETN1; 1082854; Hs.122511
1083495 KRT13; 1083495; Hs.74070
1094004 ; 1094004;
1092488 FLJ10375; 1092488; Hs.319088
1083800 IGF2R; 1083800; Hs.76473
1082305 JRK; 1082305; Hs.142296
1083650 APOB; 1083650; Hs.585
1086066 ; 1086066; Hs.124106
1076244 KIR2DL4; 1076244; Hs.166085
1094568 ; 1094568; Hs.306746
1089644 KIAA0173; 1089644; Hs.169910
1086177 ANGPT2; 1086177; Hs.115181
1078191 CLCN7; 1078191; Hs.80768
1081249 SELP; 1081249; Hs.73800
1076798 BCL10; 1076798; Hs.193516
1089336 PROC; 1089336; Hs.2351
1082923 P125; 1082923; Hs.300208
1092512 MGC1842; 1092512;
1082497 CDKN1B; 1082497; Hs.238990
1075579 E46L; 1075579; Hs.13493
1084459 P2RY4; 1084459; Hs.248157
1080389 PIK3C2B; 1080389; Hs.132463
1088906 STIP-1; 1088906; Hs.302754
1077953 TACR1; 1077953; Hs.1080
1090043 KIAA1229; 1090043; Hs.71109
1084865 SCARB1; 1084865; Hs.287283
1076256 ADAM12; 1076256; Hs.8850
1077233 TFE3; 1077233; Hs.274184
1076920 ; 1076920; Hs.306342
1093530 KIAA1007; 1093530; Hs.279949
1093737 MAN2B1; 1093737; Hs.279854
1091622 ; 1091622; Hs.301472
1087651 CALB3; 1087651; Hs.639
1085400 S100A13; 1085400; Hs.14331
1091219 ; 1091219; Hs.4892
1087709 FLJ10620; 1087709; Hs.99445
1081204 FLJ10572; 1081204; Hs.220998
1085004 ; 1085004; Hs.114293
1092598 FLJ21080; 1092598; Hs.8109
1086390 SPINLW1; 1086390; Hs.121084
1079345 CRB1; 1079345; Hs.169745
1078960 ; 1078960; Hs.293930
1080954 HSPC063; 1080954; Hs.278947
1088682 EED; 1088682; Hs.151461
1082738 EFNA1; 1082738; Hs.1624
1090676 ; 1090676; Hs.22545
1081939 SORL1; 1081939; Hs.278571
1085229 KIAA0101; 1085229; Hs.81892
1077382 ; 1077382;
1077028 GALK2; 1077028; Hs.129228
1084398 KIF11; 1084398; Hs.8878
1082532 KIAA0222; 1082532; Hs.48450
1077699 TNR; 1077699; Hs.54433
1077487 KIAA1320; 1077487; Hs.117414
1085754 DKK4; 1085754; Hs.159311
1083688 NUP133; 1083688; Hs.12457
1079008 ; 1079008;
1084185 TTK; 1084185; Hs.169840
1090099 MUC5B; 1090099;
1086889 MGST2; 1086889; Hs.81874
1093629 ; 1093629;
1078064 GPR52; 1078064; Hs.247718
1079397 UTY; 1079397; Hs.115277
1077516 ; 1077516; Hs.293916
1078417 ; 1078417; Hs.306387
1077455 NELL1; 1077455; Hs.21602
1082001 FLJ20032; 1082001;
1093606 TARBP1; 1093606; Hs.151518
1084000 PF20; 1084000; Hs.6783
1092241 CLN5; 1092241; Hs.30213
1090079 FLJ10486; 1090079; Hs.173946
1076051 IL1RL1; 1076051; Hs.66
1091663 MGC4607; 1091663; Hs.9960
1077636 CTSF; 1077636; Hs.11590
1083810 HCGIV-6; 1083810; Hs.145477
1093779 ; 1093779; Hs.302052
1077732 PRDM11; 1077732; Hs.283097
1093696 FRAT2; 1093696; Hs.140720
1088385 SPS; 1088385; Hs.124027
1083853 PKP1; 1083853; Hs.198382
1085983 SNAPC3; 1085983; Hs.164915
1091502 PIP5K2B; 1091502; Hs.6335
1090113 ; 1090113;
1084038 FLJ13322; 1084038; Hs.110298
1083798 FLJ12525; 1083798; Hs.321618
1077198 C20orf1; 1077198; Hs.9329
1088246 MLF2; 1088246; Hs.79026
1077581 HOXC8; 1077581;
1083253 HDLBP; 1083253; Hs.177516
1093412 DKFZp761A132; 1093412; Hs.301372
1093598 KIAA0794; 1093598; Hs.127287
1083428 H6PD; 1083428; Hs.194728
1087751 GPR27; 1087751; Hs.278283
1082746 MLF1; 1082746;
1085286 HPCAL1; 1085286; Hs.3618
1081255 MFAP2; 1081255; Hs.83551
1089979 KIAA1404; 1089979; Hs.200317
1082507 ; 1082507;
1090443 CCL27; 1090443; Hs.225948
1087903 FOLH1; 1087903; Hs.1915
1093740 CACNA1G; 1093740; Hs.194746
1093538 AKR1D1; 1093538; Hs.201667
1085628 SLC28A3; 1085628; Hs.306216
1089559 MGEA5; 1089559;
1093216 ; 1093216; Hs.246472
1090206 TPM2; 1090206; Hs.300772
1090435 PRKCQ; 1090435; Hs.211593
1088687 ; 1088687;
1079353 ; 1079353;
1087128 CYP2J2; 1087128; Hs.152096
1094083 NFATC1; 1094083; Hs.96149
1094419 ; 1094419; Hs 183889
1090026 CPSF5; 1090026; Hs.9605
1081251 PLEKHA4; 1081251; Hs.9469
1085039 CYP51A1; 1085039; Hs.226213
1085916 C20orf51; 1085916; Hs.187773
1086027 KIAA0415; 1086027; Hs.229950
1094210 APM2; 1094210; Hs.74120
1076600 OLFM2; 1076600; Hs.169743
1088012 FLJ23186; 1088012; Hs.30085
1092704 YBX2; 1092704; Hs.142989
1084199 ; 1084199; Hs.123060
1083897 GNB5; 1083897; Hs.155090
1088753 GRIK4; 1088753; Hs.248034
1080093 IL18BP; 1080093; Hs.325978
1090937 KEL; 1090937; Hs.157
1083560 KIAA0276; 1083560; Hs.240112
1085200 FLJ00012; 1085200; Hs.21051
1088233 C3orf1; 1088233; Hs.79530
1087939 HSD11B2; 1087939; Hs.1376
1083233 PRP17; 1083233; Hs.116674
1081282 FOXG1B; 1081282; Hs.2714
1077052 AF3P21; 1077052; Hs.102929
1092291 KIAA0140; 1092291; Hs.156016
1093344 C4BPB; 1093344; Hs.99886
1085908 ; 1085908;
1087894 PXR1; 1087894; Hs.158084
1087509 STAF65gamma; 1087509; Hs.6232
1085386 NMT1; 1085386; Hs.111039
1077552 MAP3K7; 1077552; Hs.7510
1079332 IRF7; 1079332; Hs.166120
1089839 PGS1; 1089839; Hs.162604
1081205 ROD1; 1081205; Hs.145078
1086425 ; 1086425; Hs.152939
1077428 SDHC; 1077428; Hs.3577
1080703 STC2; 1080703; Hs.155223
1092858 ; 1092858;
1082662 PRO2577; 1082662; Hs.241576
1077162 PRO0753; 1077162; Hs.302144
1075699 MFGE8; 1075699; Hs.3745
1080242 SEC23A; 1080242; Hs.272927
1079867 ; 1079867; Hs.274547
1085065 ; 1085065; Hs.288218
1075544 DXS9879E; 1075544; Hs.18212
1077050 KIAA1324; 1077050; Hs.104696
1075441 SLC17A7; 1075441; Hs.6535
1076763 ; 1076763;
1078359 RTP801; 1078359; Hs.111244
1093522 ; 1093522;
1086445 PPP2CB; 1086445; Hs.80350
1080069 pknbeta; 1080069; Hs.44101
1082299 DKFZp564I1922; 1082299; Hs.72157
1079244 OXR1; 1079244; Hs.169111
1083260 FLJ20200; 1083260; Hs.165803
1075745 ABHD2; 1075745; Hs.99364
1081791 APPBP2; 1081791; Hs.84084
1090456 IGSF4; 1090456; Hs.70337
1083924 ; 1083924; Hs.158530
1081706 TFF1; 1081706; Hs.350470
1080265 RFRP; 1080265; Hs.60473
1079791 TCN2; 1079791; Hs.84232
1090519 LOC51249; 1090519; Hs.184456
1085098 CRTAP; 1085098; Hs.155481
1082294 RTN4; 1082294; Hs.65450
1077201 IGFBP3; 1077201; Hs.77326
1088002 MADH7; 1088002; Hs.100602
1088905 AIM1; 1088905;
1077195 FLJ13621; 1077195; Hs.287583
1077793 IL19; 1077793; Hs.71979
1076111 SEPN1; 1076111; Hs.8518
1093791 FLJ10233; 1093791; Hs.16079
1078695 BBC3; 1078695; Hs.87246
1075654 EMP2; 1075654; Hs.29191
1091367 ; 1091367; Hs.296525
1079247 MGC5297; 1079247; Hs.23856
1079897 CCNB2; 1079897; Hs.194698
1089231 ZNF282; 1089231; Hs.58167
1088494 ERO1L; 1088494; Hs.25740
1075908 MR-1; 1075908; Hs.19610
1082660 LOC284677; 1082660;
1078698 LEPRE1; 1078698; Hs.10114
1092754 ; 1092754; Hs.75452
1079301 TFAP2A; 1079301; Hs.334334
1083404 GATA3; 1083404; Hs.169946
1080154 CST6; 1080154; Hs.83393
1077306 ID3; 1077306;
1090962 NRM; 1090962; Hs.57222
1091921 ; 1091921;
1084902 GPR48; 1084902; Hs.160271
1082571 KIAA0711; 1082571; Hs.5333
1075747 CDC2; 1075747; Hs.334562
1089029 CDC45L; 1089029; Hs.114311
1080185 PPEF2; 1080185; Hs.193558
1093207 SORD; 1093207; Hs.878
1086640 CBR1; 1086640; Hs.88778
1089292 ASGR1; 1089292; Hs.12056
1081715 ; 1081715; Hs.306751
1086553 SSFA2; 1086553; Hs.351355
1091202 MADH6; 1091202; Hs.153863
1080008 ; 1080008; Hs.186874
1091405 NRXN1; 1091405; Hs.22998
1078602 DRD1; 1078602; Hs.2624
1089787 FLJ23153; 1089787; Hs.44208
1094291 DKFZP564K1964; 1094291; Hs.3447
1078623 ; 1078623; Hs.13480
1080204 SIM2; 1080204; Hs.27311
1076345 DKFZP434L0117; 1076345; Hs.63795
1081660 HIST1H4L; 1081660; Hs.131957
1089799 COL11A1; 1089799; Hs.82772
1077930 PON2; 1077930; Hs.169857
1077253 NPY; 1077253; Hs.1832
1089752 PTHR1; 1089752; Hs.1019
1084603 ; 1084603; Hs.7709
1076845 PRC1; 1076845; Hs.344037
1094449 COL6A3; 1094449; Hs.80988
1078450 SFRP1; 1078450; Hs.7306
1081602 MADH5; 1081602; Hs.37501
1094614 ; 1094614; Hs.130961
1077140 ABCA12; 1077140; Hs.134585
1081654 ZNF214; 1081654; Hs.117134
1091317 ; 1091317;
1076546 RAD54B; 1076546; Hs.128501
1078987 KIAA0076; 1078987; Hs.51039
1076189 DEFB103; 1076189; Hs.283082
1079995 AF15Q14; 1079995; Hs.283099
1093913 FLJ20255; 1093913; Hs.274247
1081795 DCTN1; 1081795; Hs.74617
1084854 TIMP3; 1084854; Hs.245188
1091408 ; 1091408; Hs.239666
1081118 ; 1081118;
1092610 LOC158314; 1092610; Hs.306655
1085787 SDS; 1085787; Hs.76751
1080217 ; 1080217; Hs.335835
1092439 NEU1; 1092439; Hs.118721
1086498 CIDEB; 1086498; Hs.288835
1081357 FACL4; 1081357; Hs.81452
1076899 GNA11; 1076899; Hs.323067
1082742 SH3BP4; 1082742; Hs.17667
1082646 WNT2B; 1082646; Hs.258575
1076527 GPC3; 1076527; Hs.119651
1081517 LPLUNC2; 1081517; Hs.257045
1081392 MGAT5; 1081392; Hs.121502
1081278 UAP1; 1081278; Hs.21293
1079712 FLJ20748; 1079712; Hs.91973
1086559 FLJ10726; 1086559; Hs.268561
1092695 CENPE; 1092695; Hs.75573
1077525 NDFIP2; 1077525; Hs.30340
1083201 RPS6KC1; 1083201; Hs.30352
1083948 CIDE-3; 1083948; Hs.301002
1094047 Nup37; 1094047; Hs.5152
1078067 ; 1078067;
1094125 ; 1094125;
1084303 EDG4; 1084303; Hs.122575
1083351 CARD4; 1083351; Hs.19405
1082643 SPAG5; 1082643; Hs.16244
1079550 APTX; 1079550; Hs.14394
1080340 HBG1; 1080340; Hs.283108
1083413 DKFZP586F2423; 1083413; Hs.13659
1078396 TNFRSF17; 1078396; Hs.2556
1079097 CCNF; 1079097; Hs.1973
1076103 RASSF2; 1076103; Hs.80905
1081411 PDE4DIP; 1081411; Hs.160613
1083154 PIWIL2; 1083154; Hs.274150
1076444 HSPA1L; 1076444; Hs.80288
1078344 SULF1; 1078344; Hs.70823
1086303 N4BP2; 1086303; Hs.18685
1077304 DDX34; 1077304; Hs.151706
1080065 ; 1080065;
1083197 CPR2; 1083197; Hs.347349
1082968 EIF3S1; 1082968; Hs.173987
1080924 ESDN; 1080924; Hs.173374
1086060 KIAA0974; 1086060; Hs.44131
1090250 EPHA3; 1090250; Hs.123642
1086504 GNPI; 1086504; Hs.278500
1080451 NET1; 1080451; Hs.25155
1090765 PP1057; 1090765; Hs.108557
1079478 DLST; 1079478; Hs.296348
1076333 SSA2; 1076333; Hs.554
1087037 HSPC150; 1087037; Hs.5199
1083054 OR8B8; 1083054;
1084157 PPP1R15B; 1084157; Hs.17448
1077782 UHRF1; 1077782; Hs.108106
1081298 FLJ10849; 1081298; Hs.8768
1082766 ; 1082766; Hs.272227
1086159 CDKL5; 1086159; Hs.50905
1087101 RAB3IL1; 1087101; Hs.13759
1077595 LYPLA1; 1077595; Hs.12540
1084997 CCNA2; 1084997; Hs.85137
1078618 ; 1078618; Hs.306767
1082210 FLJ22170; 1082210; Hs.288573
1079284 DNAJA3; 1079284; Hs.6216
1076505 CRIM1; 1076505; Hs.19280
1081308 ; 1081308;
1094593 CEACAM8; 1094593; Hs.41
1076338 THY1; 1076338; Hs.125359
1076412 FLJ10803; 1076412; Hs.8173
1083005 ASCL1; 1083005; Hs.1619
1090499 LAMC2; 1090499; Hs.54451
1081390 GRIN2C; 1081390; Hs.36451
1081299 KIAA1061; 1081299; Hs.123420
1093157 IMPG1; 1093157; Hs.129882
1081593 ZFHX1B; 1081593; Hs.34871
1079438 FANCF; 1079438; Hs.65328
1089804 SCMH1; 1089804; Hs.57475
1077947 FABP4; 1077947; Hs.83213
1076506 MMP11; 1076506; Hs.155324
1080488 NUP107; 1080488; Hs.236204
1083511 ; 1083511; Hs.274585
1077829 ; 1077829;
1089390 ALB; 1089390; Hs.184411
1081213 ; 1081213; Hs.193223
1080368 ; 1080368; Hs.296678
1077454 ZNF288; 1077454; Hs.159456
1076587 ; 1076587; Hs.168232
1084839 KIAA1238; 1084839; Hs.236463
1077790 ATP2B2; 1077790; Hs.89512
1084795 PLEK2; 1084795; Hs.39957
1081346 LMO6; 1081346; Hs.166173
1080991 AP3B1; 1080991; Hs.155172
1081194 SERPIND1; 1081194; Hs.1478
1075659 DKFZP434I092; 1075659; Hs.120021
1077220 ; 1077220;
1079066 RBPSUHL; 1079066; Hs.248217
1076249 LRRC8; 1076249; Hs.173484
1077908 FLJ11101; 1077908; Hs.58382
1092243 FLJ10547; 1092243; Hs.274356
1084097 TOPBP1; 1084097; Hs.91417
1081377 IGBP1; 1081377; Hs.3631
1092461 SP329; 1092461; Hs.19928
1093846 FRSB; 1093846; Hs.9081
1092541 SLC6A7; 1092541; Hs.241597
1075591 HHLA3; 1075591; Hs.142245
1081658 ; 1081658; Hs.288965
1087110 C14orf101; 1087110; Hs.27047
1093747 E2F4; 1093747; Hs.108371
1090857 OR2L2; 1090857;
1079644 APG-1; 1079644; Hs.71992
1075794 NDRG1; 1075794; Hs.75789
1080945 FLJ10210; 1080945; Hs.183639
1082751 KIAA0595; 1082751; Hs.146957
1088530 H2AFY2; 1088530; Hs.92023
1075483 ELF5; 1075483; Hs.11713
1075539 OSBP; 1075539; Hs.24734
1078005 EYA1; 1078005; Hs.94210
1075955 DRPLA; 1075955; Hs.169488
1092511 ; 1092511;
1090552 GPR72; 1090552; Hs.272385
1075429 MCM3; 1075429; Hs.179565
1082905 PPP2R5E; 1082905; Hs.173328
1093798 EGLN3; 1093798; Hs.18878
1082800 ACCN2; 1082800; Hs.274361
1093888 FAH; 1093888; Hs.73875
1075848 SR140; 1075848; Hs.7976
1078122 ; 1078122;
1088704 FLJ14502; 1088704; Hs.181466
1077199 ; 1077199;
1093983 FOXF2; 1093983; Hs.44481
1083049 CELSR2; 1083049; Hs.57652
1088901 WDR13; 1088901; Hs.12142
1075513 ; 1075513;
1077441 APOC2; 1077441; Hs.75615
1093105 KRT18; 1093105;
1091009 FLJ23323; 1091009; Hs.59425
1078655 LOC58504; 1078655; Hs.87241
1081389 OSBPL1A; 1081389;
1085705 CRYBA2; 1085705; Hs.146549
1089521 DKFZp547D155; 1089521;
1090567 ; 1090567; Hs.306409
1090952 PPARGC1; 1090952; Hs.198468
1079527 13CDNA73; 1079527; Hs.181304
1085602 GPR66; 1085602; Hs.251384
1082429 FAM16AX; 1082429; Hs.78991
1090046 TCL1A; 1090046; Hs.2484
1083556 ZNF292; 1083556; Hs.173081
1093504 ATRN; 1093504; Hs.194019
1077650 FLJ20499; 1077650; Hs.122275
1076841 AP2A2; 1076841; Hs.19121
1092750 ARHGEF4; 1092750; Hs.6066
1077963 ; 1077963; Hs.323370
1086617 ; 1086617; Hs.306614
1080452 DKFZp434O0515; 1080452; Hs.50094
1093252 FLRT2; 1093252; Hs.48998
1088205 SLIT1; 1088205; Hs.133466
1093099 ATF7IP; 1093099; Hs.118793
1089033 KLF5; 1089033; Hs.84728
1081258 NJMU-R1; 1081258; Hs.9800
1082696 TACC3; 1082696; Hs.104019
1077033 KIAA0179; 1077033; Hs.152629
1090968 ; 1090968;
1092700 PGR; 1092700; Hs.2905
1092257 ANKH; 1092257; Hs.168640
1077047 CGR11; 1077047; Hs.159525
1079202 PTGER1; 1079202; Hs.159360
1094006 AHSG; 1094006; Hs.324746
1080653 ECE1; 1080653; Hs.288203
1075786 FBXO5; 1075786; Hs.272027
1076949 FLJ20331; 1076949; Hs.50848
1084004 KIAA1395; 1084004;
1090900 EPAS1; 1090900; Hs.8136
1080435 76P; 1080435; Hs.20621
1084144 AFG3L2; 1084144; Hs.29385
1086755 MONDOA; 1086755; Hs.52081
1091971 MGC10812; 1091971; Hs.4188
1077294 SERPINA3; 1077294; Hs.234726
1086793 CMG1; 1086793; Hs.288617
1079290 KCNN1; 1079290; Hs.158173
1085488 CD36; 1085488; Hs.75613
1082301 P2RX5; 1082301; Hs.77807
1082887 MGC14480; 1082887; Hs.37616
1086658 ; 1086658;
1080279 ; 1080279;
1087691 ATP2C1; 1087691; Hs.106778
1085513 NDUFA7; 1085513; Hs.19561
1086648 ; 1086648; Hs.7886
1085215 ; 1085215;
1082228 DHODH; 1082228; Hs.94925
1080602 TLE1; 1080602; Hs.28935
1080380 EXO1; 1080380; Hs.47504
1078995 TMF1; 1078995; Hs.267632
1084049 ALCAM; 1084049; Hs.10247
1088831 SSX5; 1088831; Hs.166198
1085389 ; 1085389; Hs.69321
1088457 ; 1088457;
1086672 ; 1086672; Hs.88878
1082261 ; 1082261; Hs.7037
1091888 ABCD2; 1091888; Hs.117852
1083409 ; 1083409;
1086167 ; 1086167; Hs.172627
1090578 NDUFB2; 1090578; Hs.198272
1083627 RW1; 1083627; Hs.75912
1085188 PRNP; 1085188; Hs.74621
1088416 ; 1088416;
1083562 ; 1083562;
1078254 HSCBCIP1; 1078254; Hs.283783
1087774 ; 1087774; Hs.272203
1090147 IRA1; 1090147; Hs.315111
1082105 SMPD1; 1082105; Hs.77813
1080921 ; 1080921;
1084261 FLJ22169; 1084261; Hs.323363
1078830 H2AFZ; 1078830; Hs.119192
1080749 CDH8; 1080749; Hs.79133
1086065 LOC88745; 1086065; Hs.283636
1080273 ; 1080273; Hs.28659
1081704 DDXx; 1081704; Hs.95665
1084487 KIAA0317; 1084487; Hs.20126
1086020 TMEM5; 1086020; Hs.112986
1082236 MIPEP; 1082236; Hs.68583
1088745 LOC90990; 1088745; Hs.92679
1084294 C20orf21; 1084294; Hs.11747
1085920 FLJ11457; 1085920; Hs.126707
1092046 BTG4; 1092046; Hs.128180
1087188 GGPS1; 1087188; Hs.55498
1090452 ; 1090452; Hs.55977
1088659 ACTL7A; 1088659; Hs.123530
1088996 ; 1088996;
1084538 ; 1084538;
1086735 WASF3; 1086735; Hs.82318
1077444 AVPR1B; 1077444; Hs.1372
1083652 APPBP1; 1083652; Hs.61828
1089935 KIAA1649; 1089935; Hs.334836
1085751 WSB1; 1085751; Hs.187991
1080612 PCANAP7; 1080612; Hs.27495
1080747 LRBA; 1080747; Hs.62354
1085073 ; 1085073;
1090078 HYAL4; 1090078; Hs.28673
1088856 UTS2; 1088856; Hs.162200
1090379 APEX2; 1090379; Hs.154149
1088407 ; 1088407; Hs.6634
1091880 DKFZp571K0837; 1091880;
1084592 STX16; 1084592; Hs.102178
1091712 ; 1091712;
1075733 RBPMS; 1075733; Hs.80248
1090558 MC3R; 1090558; Hs.248018
1081957 ; 1081957;
1082289 PPOX; 1082289; Hs.100016
1089590 PARG; 1089590; Hs.91390
1082157 FGF8; 1082157;
1090236 CAPN11; 1090236; Hs.225953
1082044 GPX3; 1082044; Hs.336920
1081930 SET07; 1081930;
1084498 NEDD5; 1084498; Hs.155595
1075488 KIAA0057; 1075488; Hs.153954
1078878 SLC25A10; 1078878; Hs.285829
1086660 LOC148894; 1086660; Hs.348515
1089189 DHCR7; 1089189; Hs.11806
1082458 ; 1082458; Hs.153527
1082207 ; 1082207;
1087728 CARKL; 1087728; Hs.190207
1082491 FLJ22595; 1082491; Hs.287702
1091747 MGC10198; 1091747; Hs.24654
1077803 GRM5; 1077803; Hs.167185
1091664 ; 1091664;
1087542 SYPL; 1087542; Hs.80919
1091977 SIAT6; 1091977; Hs.48793
1085052 GEM; 1085052; Hs.79022
1089385 MYLK; 1089385; Hs.211582
1090423 FLJ12998; 1090423; Hs.343627
1080636 PCSK4; 1080636; Hs.46884
1079288 FLJ11042; 1079288; Hs.274208
1091520 ; 1091520;
1089661 LOC152559; 1089661; Hs.26860
1091078 FH; 1091078; Hs.75653
1090229 CHAC; 1090229; Hs.53542
1089441 RA410; 1089441; Hs.27023
1089045 FLJ20364; 1089045; Hs.32471
1082047 H326; 1082047; Hs.110707
1086880 SMARCF1; 1086880; Hs.123090
1082436 FLJ23598; 1082436; Hs.147377
1091918 ; 1091918;
1087180 RPC155; 1087180; Hs.249212
1092047 GMNN; 1092047; Hs.234896
1083792 SEC22L1; 1083792; Hs.50785
1087943 ALOX15; 1087943; Hs.73809
1090797 FLJ14888; 1090797; Hs.29863
1093672 NUP160; 1093672; Hs.22559
1089106 ANKRD7; 1089106; Hs.73073
1085210 FLJ10874; 1085210; Hs.30318
1078992 NUP155; 1078992; Hs.23255
1091491 SLC17A1; 1091491; Hs.100001
1093254 GATA4; 1093254; Hs.243987
1078650 GW112; 1078650; Hs.273321
1088191 ARL1; 1088191; Hs.242894
1090255 MSI1; 1090255; Hs.158311
1079089 PCL1; 1079089; Hs.278627
1083102 VIP; 1083102; Hs.53973
1082695 TBC1D2; 1082695; Hs.135917
1079149 COL8A1; 1079149; Hs.114599
1089299 ITGA2; 1089299; Hs.271986
1082187 USP7; 1082187; Hs.78683
1086599 ; 1086599; Hs.283725
1090767 ; 1090767;
1091749 FAT; 1091749; Hs.166994
1090439 SLC30A5; 1090439; Hs.129445
1084095 TMOD; 1084095; Hs.170453
1090707 LUM; 1090707; Hs.79914
1082947 ; 1082947; Hs.46801
1090696 MAPRE3; 1090696; Hs.172740
1092150 PXN; 1092150; Hs.102497
1086099 VCAM1; 1086099; Hs.109225
1082853 DOCK2; 1082853; Hs.17211
1093120 ; 1093120; Hs.38034
1078306 SNCAIP; 1078306; Hs.24948
1075588 GFRA1; 1075588; Hs.105445
1091908 ; 1091908;
1077359 KIAA0419; 1077359; Hs.279912
1093496 MSH6; 1093496; Hs.3248
1082240 MT1L; 1082240; Hs.94360
1087845 PLS3; 1087845; Hs.4114
1091903 KIAA1169; 1091903; Hs.26440
1091951 WISP2; 1091951; Hs.194679
1083887 UBE2N; 1083887; Hs.75355
1091954 ADAM29; 1091954; Hs.126838
1083354 RFP2; 1083354; Hs.151428
1092523 ; 1092523; Hs.226440
1091498 LEPREL2; 1091498; Hs.46458
1086127 SEC3; 1086127; Hs.22394
1077056 ENPP1; 1077056;
1088671 ; 1088671;
1092588 BACE2; 1092588; Hs.271411
1087190 GABRP; 1087190; Hs.70725
1082955 SEMA3C; 1082955; Hs.171921
1084345 HEMGN; 1084345; Hs.176626
1087244 KIAA0169; 1087244;
1094087 KLK3; 1094087;
1076816 LOC51049; 1076816; Hs.129705
1079823 LOC92312; 1079823; Hs.279727
1084550 APLP1; 1084550; Hs.74565
1093686 KIAA0323; 1093686; Hs.7911
1092494 ; 1092494; Hs.12385
1082997 MAPK4; 1082997; Hs.269222
1086100 S100P; 1086100; Hs.2962
1087653 ECEL1; 1087653; Hs.26880
1082033 CSTF3; 1082033; Hs.180034
1084430 HAKAI; 1084430; Hs.292767
1084745 FLNC; 1084745; Hs.58414
1076664 ; 1076664; Hs.288660
1084601 AVP; 1084601; Hs.89648
1081751 NTS; 1081751; Hs.80962
1091105 KCNQ2; 1091105; Hs.4975
1079442 SCOC; 1079442; Hs.286013
1076649 CNTN1; 1076649; Hs.143434
1093350 UNC13; 1093350; Hs.155001
1080595 SDS3; 1080595; Hs.20104
1092671 ; 1092671;
1084752 TGFBR1; 1084752; Hs.220
1080199 ARHE; 1080199; Hs.6838
1081247 CSNK2A1; 1081247; Hs.155140
1092892 MTSG1; 1092892; Hs.7946
1084598 S100A3; 1084598; Hs.2961
1081464 MGC861; 1081464; Hs.208912
1093002 EDG3; 1093002; Hs.248107
1079052 OPN3; 1079052; Hs.279926
1094145 FBXO21; 1094145; Hs.184227
1081324 DKFZp762E1312; 1081324; Hs.104859




1094544 RHOBTB3; 1094544; Hs.10432
1082906 CLIC4; 1082906; Hs.25035
1093898 CDK2; 1093898; Hs.19192
1082138 TPARL; 1082138; Hs.236510
1081027 ARHGEF12; 1081027; Hs.6582
1078275 BCMP1; 1078275; Hs.8769
1079860 C4orf7; 1079860;
1075863 ; 1075863; Hs.288741
1084255 WNT8B; 1084255; Hs.137595
1076992 KIAA1524; 1076992; Hs.151343
1086595 HSPC228; 1086595; Hs.267288
1079830 ; 1079830; Hs.27801
1093948 DIM1; 1093948; Hs.5074
1093952 NS; 1093952; Hs.279923
1078457 C14orf136; 1078457; Hs.164866
1083224 ; 1083224; Hs.287499
1076698 CGI-143; 1076698; Hs.13880
1079905 JRKL; 1079905; Hs.105940
1084401 HUMAUANTIG; 1084401; Hs.75528
1086503 ZNF268; 1086503; Hs.183291
1081114 ; 1081114; Hs.144871
1082735 FBXW2; 1082735; Hs.13755
1081193 PDE4DIP; 1081193; Hs.265848
1081824 MGC16824; 1081824; Hs.5320
1084860 HIST1H4E; 1084860; Hs.240135
1080149 CTNND2; 1080149; Hs.80220
1076056 FGB; 1076056; Hs.7645
1083513 ; 1083513;
1079659 ; 1079659; Hs.288888
1076885 PTPRB; 1076885; Hs.123641
1080999 THBS2; 1080999; Hs.108623
1084105 LIV-1; 1084105; Hs.79136
1079836 KLK2; 1079836; Hs.181350
1091310 FLJ20222; 1091310; Hs.98017
1084890 FLJ20986; 1084890; Hs.324507
1094296 EEG1; 1094296; Hs.279894
1083129 UBE3A; 1083129; Hs.301667
1084716 ; 1084716; Hs.333421
1094316 ; 1094316; Hs.287451
1076895 KIF14; 1076895; Hs.3104
1094248 FLJ23360; 1094248; Hs.161279
1092069 HEPH; 1092069; Hs.31720
1084648 NGFR; 1084648; Hs.1827
1091894 KANK; 1091894; Hs.77546
1094504 DNM1L; 1094504; Hs.180628
1080405 MRPL40; 1080405; Hs.19500
1081028 B4GALT6; 1081028; Hs.159140
1087429 FLJ10283; 1087429; Hs.284216
1078146 PTTG1; 1078146; Hs.252587
1087578 PHKA2; 1087578; Hs.54941
1078593 CEACAM1; 1078593; Hs.50964
1082441 KDELR2; 1082441; Hs.118778
1093594 NT5C; 1093594;
1080458 ; 1080458; Hs.10862
1080450 APOB; 1080450; Hs.585
1079685 EHD3; 1079685; Hs.87125
1075782 TRIM45; 1075782; Hs.301526
1093188 NMA; 1093188; Hs.78776
1075779 CDC6; 1075779; Hs.69563
1080644 EDNRB; 1080644; Hs.82002
1084998 DFFA; 1084998; Hs.105658
1093303 ADNP; 1093303; Hs.3657
1092954 CST3; 1092954; Hs.135084
1092618 ; 1092618;
1075498 MRE11A; 1075498; Hs.20555
1088732 TCF4; 1088732; Hs.326198
1084380 PON3; 1084380; Hs.296259
1086340 KCNMB1; 1086340; Hs.93841
1090264 ; 1090264;
1082855 SEMA4B; 1082855; Hs.9598
1088760 PDHA2; 1088760; Hs.131361
1090494 ZNF238; 1090494; Hs.69997
1081087 CLN2; 1081087; Hs.20478
1088683 SPF30; 1088683; Hs.79968
1076612 PRO0971; 1076612; Hs.152316
1093096 CRKL; 1093096; Hs.37078
1081448 BLu; 1081448; Hs.167380
1081854 ID3; 1081854; Hs.76884
1081454 POP5; 1081454; Hs.279913
1081900 TLR9; 1081900; Hs.87968
1082599 ; 1082599;
1086707 SCA7; 1086707; Hs.108447
1081544 FLJ23548; 1081544; Hs.22895
1078517 ; 1078517;
1075438 PPIH; 1075438; Hs.9880
1090607 ; 1090607;
1082102 TTRAP; 1082102; Hs.46847
1078506 TFF3; 1078506; Hs.82961
1091659 POFUT1; 1091659; Hs.178292
1080909 BM039; 1080909; Hs.283532
1076341 FLJ10815; 1076341; Hs.10499
1086952 C22orf19; 1086952; Hs.75361
1079059 ; 1079059;
1083878 SDHD; 1083878; Hs.168289
1080263 IFIT2; 1080263;
1090648 CDK4; 1090648; Hs.95577
1079412 C20orf177; 1079412; Hs.286184
1079599 TM4SF3; 1079599; Hs.84072
1082949 COL4A3; 1082949; Hs.530
1090239 HRC; 1090239; Hs.1480
1091987 FLJ13646; 1091987; Hs.21081
1092003 HOMER1; 1092003; Hs.337737
1075493 HSPG2; 1075493; Hs.211573
1082311 PRO0659; 1082311; Hs.6451
1093806 ATP6V1B1; 1093806; Hs.64173
1090152 VIPR2; 1090152; Hs.2126
1083840 TM9SF2; 1083840; Hs.28757
1086475 C20orf67; 1086475; Hs.272814
1083950 ; 1083950;
1093493 ; 1093493; Hs.325960
1084394 SERPINA7; 1084394; Hs.76838
1090699 NEUGRIN; 1090699; Hs.323467
1083336 ZMPSTE24; 1083336; Hs.25846
1085805 ; 1085805; Hs.242038
1091003 PRKAR1A; 1091003; Hs.183037
1079379 C4orf1; 1079379; Hs.270956
1089207 ; 1089207;
1088891 GBF1; 1088891; Hs.155499
1075874 LOC147991; 1075874; Hs.29808
1075590 MGC10500; 1075590; Hs.271599
1088702 GPR75; 1088702; Hs.40763
1078206 FKRP; 1078206; Hs.193261
1075444 C1QR1; 1075444; Hs.97199
1075785 STK12; 1075785; Hs.180655
1082351 PLXNA2; 1082351; Hs.300622
1077517 ; 1077517; Hs.257696
1076050 RARB; 1076050; Hs.171495
1075439 LOC83693; 1075439; Hs.171937
1091423 HSMCR30; 1091423; Hs.122744
1093746 TACSTD1; 1093746; Hs.692
1091298 MMD; 1091298; Hs.79889
1088691 FLJ22655; 1088691; Hs.115497
1079761 FLJ23091; 1079761; Hs.250746
1090251 TNFRSF11B; 1090251; Hs.81791
1093290 HBG1; 1093290; Hs.266959
1077897 ; 1077897; Hs.105664
1094103 STRAIT11499; 1094103; Hs.236556
1083014 NEK9; 1083014; Hs.7200
1091499 ROBO1; 1091499; Hs.301198
1081150 PKD1; 1081150; Hs.75813
1092806 KCNE1L; 1092806; Hs.146372
1077740 ATP8B2; 1077740; Hs.43577
1090233 GRSF1; 1090233; Hs.309763
1093745 RDX; 1093745; Hs.263671
1090650 BK65A6.2; 1090650; Hs.131819
1093995 Rab11-FIP3; 1093995; Hs.119004
1076916 ; 1076916;
1091191 COPZ2; 1091191; Hs.37482
1090489 CL640; 1090489; Hs.44563
1083256 HSNOV1; 1083256; Hs.9711
1090756 C13orf7; 1090756; Hs.10711
1090870 BID; 1090870; Hs.315689
1076010 PRKWNK1; 1076010; Hs.349096
1093792 F11R; 1093792; Hs.286218
1087796 SH2B; 1087796; Hs.15744
1078662 KIAA0406; 1078662; Hs.158249
1089566 ; 1089566;
1090257 RAB3GAP; 1090257; Hs.227881
1093502 GAB1; 1093502; Hs.239706
1092785 PTK9; 1092785; Hs.82643
1089723 BIVM; 1089723; Hs.288809
1089718 FLJ22789; 1089718;
1086410 PRO2831; 1086410; Hs.250568
1078940 HBZ; 1078940; Hs.272003
1084390 M6PR; 1084390; Hs.75709
1089636 SQV7L; 1089636; Hs.348511
1079949 ROBO4; 1079949; Hs.111518
1091406 TBXAS1; 1091406; Hs.2001
1077059 ; 1077059; Hs.180059
1091985 C20orf97; 1091985; Hs.26802
1080977 HAS2; 1080977; Hs.159226
1077489 ZDHHC4; 1077489; Hs.5268
1081497 PWDMP; 1081497; Hs.288821
1081505 ODZ1; 1081505; Hs.23796
1091288 FLJ23751; 1091288; Hs.37443
1089552 ETBR-LP-2; 1089552; Hs.132049
1081555 NOTCH2; 1081555;
1081662 FLJ20695; 1081662; Hs.5420
1085302 LIFR; 1085302; Hs.2798
1076265 ; 1076265; Hs.61658
1085404 ; 1085404;
1081722 LOC116068; 1081722; Hs.136235
1081564 ; 1081564;
1086551 SH3BP2; 1086551; Hs.167679
1081700 ; 1081700;
1091706 PFN2; 1091706; Hs.91747
1081764 FLJ23416; 1081764; Hs.306900
1081605 NAGLU; 1081605; Hs.50727
1093663 GPR3; 1093663; Hs.66542
1094499 MYOM2; 1094499; Hs.79227
1092229 MCM6; 1092229; Hs.155462
1083540 LOC220963; 1083540; Hs.238927
1092881 ZNF319; 1092881; Hs.129268
1094242 DNAH9; 1094242;
1077159 NMES1; 1077159;
1085057 ; 1085057; Hs.222024
1083387 PCBD; 1083387; Hs.3192
1084152 NPY5R; 1084152; Hs.158330
1079194 KRT18; 1079194; Hs.65114
1081992 SNX3; 1081992; Hs.12102
1082915 ; 1082915; Hs.270124
1094340 MGC11034; 1094340;
1086315 LOC148936; 1086315; Hs.273099
1083096 EDG5; 1083096; Hs.202672
1094487 MAN2A1; 1094487; Hs.32965
1087703 ADAM11; 1087703; Hs.6088
1083595 DKFZP434F122; 1083595; Hs.159352
1080171 SFRS2IP; 1080171; Hs.139315
1083598 DNCH1; 1083598; Hs.7720
1094298 BNIP2; 1094298; Hs.155596
1094415 SIT; 1094415; Hs.88012
1076625 ; 1076625; Hs.288742





1093763 KCNA10; 1093763; Hs.248140
1093529 ; 1093529; Hs.306574
1090292 SERPINI2; 1090292; Hs.158308
1079189 CAT; 1079189; Hs.76359
1083852 EPS8R1; 1083852; Hs.28907
1082665 ; 1082665; Hs.272249
1088235 FNTA; 1088235; Hs.349822
1080944 MFN2; 1080944; Hs.3363
1078346 KIAA0545; 1078346; Hs.129943
1078603 SLC6A5; 1078603; Hs.136557
1084047 KIAA1695; 1084047; Hs.288841
1094201 CSNK1G3; 1094201; Hs.129206
1090450 SNT-1; 1090450; Hs.251394
1085516 ; 1085516;
1093813 ; 1093813; Hs.296484
1078251 SRGAP2; 1078251; Hs.7977
1081055 WNT5A; 1081055; Hs.152213
1081105 EDN3; 1081105; Hs.1408
1091026 CALD1; 1091026; Hs.325474
1083600 SORBS1; 1083600; Hs.108924
1094533 C20orf14; 1094533; Hs.31334
1094331 HDAC2; 1094331; Hs.3352
1083679 ; 1083679;
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BMC Infectious Diseases 2004, 4:34 http://www.biomedcentral.com/1471-2334/4/34Table 1: Representation of selected immune-related genes upregulated during the first 12 hours post-infection.
Gene Unique Gene ID. Function Expression range (log2) Cluster no.
Immune Response Genes:
TGFBR1 Hs.220 Cytokine proinflammatory 10.66 4
CD36 Hs.75613 Macrophage receptor 8.61 3
TLR 9 Hs.87968 Macrophage activation 7.11 7
MST Hs.349110 Macrophage activation 7.07 6
IL 19 Hs.71979 Cytokine, proinflammatory 6.86 9
C1QR Hs.97199 Innate response 6.31 7
C6 Hs.1282 Innate response 6.22 6
GATA3 Hs.169946 Inflamation signaling 6.14 9
MMD Hs.79889 Monocyte to macrophage 6.13 7
CCL 25 Hs.50404 Chemokine, trafficking 6.10 6
CXCL 12 Hs.237356 Chemokine, trafficking 5.86 6
CCL 27 Hs.225948 Chemokine, trafficking 5.34 6
C4BPB Hs.99886 Innate response 5.12 6
CCR 4 Hs.184926 Chemokine, trafficking 5.11 3
CCL 4 Hs.75703 Chemokine, trafficking 4.62 3
IL 17C Hs.110040 Chemokine, trafficking 4.25 14
IL 1β Hs.126256 Cytokine, proinflammatory 4.20 3
MRC 2 Hs.7835 Macrophage activation 3.20 7
CXCL 9 Hs.77367 Chemokine, trafficking 3.00 2
CCL 20 Hs.75498 Chemokine, trafficking 2.88 3
CXCL 3 Hs.89690 Chemokine, trafficking 2.79 13
CXCL 2 Hs.75765 Chemokine, trafficking 2.78 3
CD 14 Hs.75627 Macrophage activation 2.73 3
IL 8 Hs.624 Chemokine, trafficking 2.70 3
NFκβ1 Hs.83428 Macrophage activation 2.61 13
CCL 22 Hs.97203 Chemokine, trafficking 2.60 3
CCR 7 Hs.1652 Chemokine, trafficking 2.55 9
Blood Coagulation Genes:
SERPINA3 Hs.234726 Inflammation activation 9.39 3
SERPINI2 Hs.158308 Proteinase inhibitor 8.82 11
TBXAS 1 Hs.2001 Blood coagulation 7.70 8
FGB Hs.7645 Fibrin 6.75 4
SERPIND1 Hs.1478 Blood coagulation 6.69 14
SERPINI1 Hs.78589 Proteinase inhibitor 6.68 6
SERPINA7 Hs.76838 Proteinase inhibitor 6.60 7
GP1bα Hs.1472 Platelet aggregation 5.68 6
PROC Hs.2351 Blood coagulation 5.63 6
Factor 10 Hs.47913 Blood coagulation 4.66 6
Factor 2 Hs.76530 Blood coagulation 4.50 6
GP 9 Hs.1144 Platelet aggregation 4.02 6
Factor 3 Hs.62192 Blood coagulation 3.60 2
FGG Hs.75431 Fibrin 2.60 3
SEPPINE1 Hs.82085 Anti-Fibrinolysis 1.75 9
Signaling Genes:
UNC 13 Hs.155001 Apoptosis induction 11.19 4
CARD 4 Hs.19405 Apoptosis, caspase activator 10.68 14
TNFRSF17 Hs.2556 Apoptosis signaling 10.19 14
ARL 1 Hs.242894 Cell-cell signaling 8.66 2
LGALS 3 Hs.79339 Signaling, scavenger activity 7.65 6
FAT Hs.166994 Tumour suppressor 7.15 2
TNFSF9 Hs.1524 Apoptosis signaling 6.85 6
BBC3 Hs.87246 Apoptosis signaling 6.77 9
TNFRSF13β Hs.158341 Apoptosis signaling 6.49 6
DDX24 Hs.155986 Apoptosis signaling 6.11 6
TNFRSF11β Hs.81791 Apoptosis signaling 6.11 7
TNFRSF10β Hs.51233 Apoptosis signaling 6.09 6
BNIP2 Hs.155596 Apoptosis signaling 5.81 1
MGST 2 Hs.81874 Cell-cell signaling 5.50 6Page 7 of 11
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BMC Infectious Diseases 2004, 4:34 http://www.biomedcentral.com/1471-2334/4/34It is interesting to note that the TLR9 was highly expressed
in comparison to other TLR receptors, implying some
degree of TLR specificity for the virus (Fig. 3A). TLR9 is
known to respond to CpG signaling motifs (GTCGTT)
[37-39] and one possibility is that the virus is activating
directly through this mechanism. In support of this, we
found that the SARS-CoV viral sequence contains the
highest number (7 copies) of such specific signaling
motifs compared to other coronaviruses and significantly
more than several other viruses involved in respiratory
diseases (Fig. 3B). It is conceivable that TLR9 may be aid-
ing host recognition of the virus via the CpG groups and
contributing to the initiation of the innate host inflamma-
tory response. An alternative explanation is that TLR9 is
being stimulated by mechanisms unrelated to CpG
recognition.
The emerging picture from this study implicates a central
role for the immune response in the pathobiology of a
SARS infection. While detailed in vivo studies of the host
response are now required, the in vitro model described
here will allow responses to specific modulators (such as
therapeutics) to be investigated. In future developments
of the model, it will be interesting to compare the host
response to different SARS-CoV isolates with inactivated
preparations of the virus. In other diseases, in vitro models
have revealed a number of key processes relevant to the
clinical diseases [9,12,13] and it is likely that the
responses identified here will prove to be equally impor-
tant. Although some clinical parameters have now been
used as prognostic markers [40-42], further study of the
regulatory mechanisms for chemokine-cytokine
production will likely improve their accuracy and perhaps
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CUL 4 Hs.183874 Tumour suppressor 5.35 6
BAF 53A Hs.274350 Cell-cell signaling 5.26 6
MAPK 1 Hs.324473 Apoptosis induction 5.11 14
CUL 2 Hs.82919 Tumour suppressor 5.09 6
P2RX 1 Hs.41735 Apoptosis, ion channel activity 4.43 6
TYROBP Hs.9963 Intracellular receptor signaling 2.51 13
CNIH Hs.201673 Intracellular signaling 2.13 9
ADRα1A Hs.52931 Cell-cell signaling 2.08 3
DAPK 1 Hs.153924 Apoptosis induction 2.01 9
Defense-related Genes:
TFF 1 Hs.350470 Defense response, maintenance 7.65 9
TFF 3 Hs.82961 Extracellular defense response 6.98 7
GAGE 1 Hs.128231 Cellular defense response 6.82 6
DEFβ3 Hs.283082 Extracellular defense response 6.01 5
RU 2 Hs.61345 Extracellular defense response 5.83 6
DEFα4 Hs.2582 Extracellular defense response 5.81 6
Interferons-related Genes:
IFNαR1 Hs.1513 JAK-STAT cascade, recptor 5.41 8
IRF 7 Hs.166120 Transcription regulation 5.05 6
IF 144 Hs.82316 Invasive growth response 2.69 5
IRF 6 Hs.11801 Transcription regulation 2.06 14
IL 18 Hs.83077 Angiogenesis 1.76 6
ISGF3γ Hs.1706 Regulatory 1.28 9
IRF 5 Hs.334450 Transcription regulation 1.23 9
IFNαR2 Hs.86958 Receptor activity 1.06 2
IFNγR1 Hs.180866 Receptor activity 0.80 5
IFNγ Hs.856 Growth regulation 0.53 4
IRF 3 Hs.75254 Transcription regulation 0.40 5
IRF 2 Hs.83795 Transcription regulation 0.32 4
IRF 1 Hs.80645 Transcription regulation 0.30 3
Order is arranged from the highest to lowest value based on the expression range (log2).
Table 1: Representation of selected immune-related genes upregulated during the first 12 hours post-infection. (Continued)Page 8 of 11
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Expression of TLR9 in response to SARS-CoV infection. A. Expression range (log2) for TLR9, TLR2 and TLR4. The expression 
range for TLR9 was greater than expected (* represents a P-value for TLR9 of 0.016). B. Comparison of the CpG motif 
(GTCGTT) copy number in coronaviruses and other viruses linked to respiratory diseases. Accession numbers are as follows: 
SARS coronavirus SIN2500 – AY283794, Human coronavirus 229E – NC_002645, Murine hepatitis virus – NC_001846, Avian 
infectious bronchitis virus – NC_001451, Bovine coronavirus – NC_003045, Human rhinovirus B – NC_001490, Human 
























Virus (GTCGTT) copy number
Coronaviruses:
SARS coronavirus GIS 2500 7
Human coronavirus 229E 3
Murine hepatitis virus 6
Avian infectious bronchitis virus 3
Bovine coronavirus 4
Viruses linked to respiratory diseases:
Human rhinovirus B 0
Human parainfluenza virus 1 0
Human respiratory syncytial virus 0
Human metapnuemovirus 0
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Additional File 1
List of all immune related genes after SARS-CoV infection Compre-
hensive list of 1087 immune related genes that were altered in PBMCs in 
response to SARS-CoV infection at 4 hours, 8 hours, 12 hours, and 24 
hours. Genes were grouped and ordered using the algorithm described in 
Methods. Rows represent individual genes, columns represent individual 
time points. Each cell in the matrix represents the mean expression level 
from 3 subjects for a gene feature at a particular time point (non-infected 
PBMCs responses have been subtracted from infected responses). The red 
and green color bars reflect high and low expression levels respectively, 
while black indicates equivalent expression level. The magnitude of the 
log-transformed ratio is reflected by the degree of color saturation. The line 
graph indicates the average expression ratios for each group. The area 
above the axis indicates upregulation, while the area under the axis means 
downregulation.
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